Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial
Copyright © 2017 Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: Community-acquired pneumonia (CAP) is treated with penicillin in some northern European countries.
OBJECTIVES: To evaluate whether high-dose penicillin V is as effective as high-dose amoxicillin for the treatment of non-severe CAP.
DESIGN: Multicentre, parallel, double-blind, controlled, randomized clinical trial.
SETTING: 31 primary care centers in Spain.
PARTICIPANTS: Patients from 18 to 75 years of age with no significant associated comorbidity and with symptoms of lower respiratory tract infection and radiological confirmation of CAP were randomized to receive either penicillin V 1.6 million units, or amoxicillin 1000mg three times per day for 10 days.
MAIN MEASUREMENTS: The main outcome was clinical cure at 14 days, and the primary hypothesis was that penicillin V would be non-inferior to amoxicillin with regard to this outcome, with a margin of 15% for the difference in proportions. EudraCT register 2012-003511-63.
RESULTS: A total of 43 subjects (amoxicillin: 28; penicillin: 15) were randomized. Clinical cure was observed in 10 (90.9%) patients assigned to penicillin and in 25 (100%) patients assigned to amoxicillin with a difference of -9.1% (95% CI, -41.3% to 6.4%; p=.951) for non-inferiority. In the intention-to-treat analysis, amoxicillin was found to be 28.6% superior to penicillin (95% CI, 7.3-58.1%; p=.009 for superiority). The number of adverse events was similar in both groups.
CONCLUSIONS: There was a trend favoring high-dose amoxicillin versus high-dose penicillin in adults with uncomplicated CAP. The main limitation of this trial was the low statistical power due to the low number of patients included.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Atencion primaria - 51(2019), 1 vom: 16. Jan., Seite 32-39 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Llor, Carl [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.04.2020 Date Revised 10.04.2020 published: Print-Electronic EudraCT: 2012-003511-63 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.aprim.2017.08.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM277296838 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM277296838 | ||
| 003 | DE-627 | ||
| 005 | 20231225013908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.aprim.2017.08.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0924.xml |
| 035 | |a (DE-627)NLM277296838 | ||
| 035 | |a (NLM)29061311 | ||
| 035 | |a (PII)S0212-6567(17)30234-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Llor, Carl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2020 | ||
| 500 | |a Date Revised 10.04.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a EudraCT: 2012-003511-63 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: Community-acquired pneumonia (CAP) is treated with penicillin in some northern European countries | ||
| 520 | |a OBJECTIVES: To evaluate whether high-dose penicillin V is as effective as high-dose amoxicillin for the treatment of non-severe CAP | ||
| 520 | |a DESIGN: Multicentre, parallel, double-blind, controlled, randomized clinical trial | ||
| 520 | |a SETTING: 31 primary care centers in Spain | ||
| 520 | |a PARTICIPANTS: Patients from 18 to 75 years of age with no significant associated comorbidity and with symptoms of lower respiratory tract infection and radiological confirmation of CAP were randomized to receive either penicillin V 1.6 million units, or amoxicillin 1000mg three times per day for 10 days | ||
| 520 | |a MAIN MEASUREMENTS: The main outcome was clinical cure at 14 days, and the primary hypothesis was that penicillin V would be non-inferior to amoxicillin with regard to this outcome, with a margin of 15% for the difference in proportions. EudraCT register 2012-003511-63 | ||
| 520 | |a RESULTS: A total of 43 subjects (amoxicillin: 28; penicillin: 15) were randomized. Clinical cure was observed in 10 (90.9%) patients assigned to penicillin and in 25 (100%) patients assigned to amoxicillin with a difference of -9.1% (95% CI, -41.3% to 6.4%; p=.951) for non-inferiority. In the intention-to-treat analysis, amoxicillin was found to be 28.6% superior to penicillin (95% CI, 7.3-58.1%; p=.009 for superiority). The number of adverse events was similar in both groups | ||
| 520 | |a CONCLUSIONS: There was a trend favoring high-dose amoxicillin versus high-dose penicillin in adults with uncomplicated CAP. The main limitation of this trial was the low statistical power due to the low number of patients included | ||
| 650 | 4 | |a Equivalence Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adultos | |
| 650 | 4 | |a Adults | |
| 650 | 4 | |a Amoxicilina | |
| 650 | 4 | |a Amoxicillin | |
| 650 | 4 | |a Community-acquired pneumonia | |
| 650 | 4 | |a Ensayo clínico aleatorizado | |
| 650 | 4 | |a Neumonía adquirida en la comunidad | |
| 650 | 4 | |a Penicilina | |
| 650 | 4 | |a Penicillin | |
| 650 | 4 | |a Randomized controlled trial | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Amoxicillin |2 NLM | |
| 650 | 7 | |a 804826J2HU |2 NLM | |
| 650 | 7 | |a Penicillin V |2 NLM | |
| 650 | 7 | |a Z61I075U2W |2 NLM | |
| 700 | 1 | |a Pérez, Almudena |e verfasserin |4 aut | |
| 700 | 1 | |a Carandell, Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a García-Sangenís, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Rezola, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Llorente, Marian |e verfasserin |4 aut | |
| 700 | 1 | |a Gestoso, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Bobé, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Román-Rodríguez, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Cots, Josep M |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Miravitlles, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Morros, Rosa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Atencion primaria |d 1991 |g 51(2019), 1 vom: 16. Jan., Seite 32-39 |w (DE-627)NLM012612324 |x 1578-1275 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2019 |g number:1 |g day:16 |g month:01 |g pages:32-39 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.aprim.2017.08.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2019 |e 1 |b 16 |c 01 |h 32-39 | ||